Gemphire Therapeutics and NeuroBo Pharmaceuticals announce merger agreement

04:09 EDT 25 Jul 2019 | Pharmaceutical Business Review

Upon completion of the merger, Gemphire will change its name to NeuroBo Pharmaceuticals, Inc., and plans to change its ticker symbol on the Nasdaq Capital Market to “NRBO.”

The post Gemphire Therapeutics and NeuroBo Pharmaceuticals announce merger agreement appeared first on Pharmaceutical Business review.

More From BioPortfolio on "Gemphire Therapeutics and NeuroBo Pharmaceuticals announce merger agreement"